Lung Cancer

The new report found no evidence that second-generation tyrosine kinase inhibitors (TKIs) were more likely to lead to Clostridioides difficile infection (CDI) in patients with lung cancer.

The development of 2 panels measuring levels of tumor-associated autoantibodies (TAAbs) has promise for predicting therapeutic response and adverse events for patients with advanced non–small cell lung cancer (NSCLC) after immune checkpoint inhibitor–based treatment.

This study investigated the effects of antimicrobial therapy among patients with non–small cell lung cancer (NSCLC) who received immunotherapy with a checkpoint inhibitor or chemotherapy plus immunotherapy (CIT).

The study, based on care in Japan, found patients would be more quickly referred for targeted therapy.

Differences in overall survival between cannabis users and those who did not use the plant were small and could be explained by differences in the make-ups of the 2 cohorts of patients with non-small cell lung cancer, researchers said.

The study offers guidance to clinicians treating the roughly 10% of patients with rare EGFR mutations.

A recent study stresses the importance of routine CT screening for improving lung cancer survival outcomes.

The State of Lung Cancer 2022 report issued by the American Lung Association illustrates aspects of diagnosis and care that require additional attention to address disparities and increase nationwide screening and treatment engagement while reducing risk factor exposure.

Lung cancer is the number one cause of cancer-related deaths among women in the United States, yet relatively little research funding is spent on the issue, the authors of a new study say.

The FDA approved cemiplimab (Libtayo) in combination with platinum-based chemotherapy for the first-line treatment of advanced non–small cell lung cancer (NSCLC) with no EGFR, ALK or ROS1 aberrations.

A new report underscores how treatment decisions for non-small cell lung cancer (NSCLC) affect patients’ health care utilization and costs.

Immune checkpoint inhibitors, either alone or in combination with chemotherapy, were associated with better outcomes in non–oncogene-addicted non–small cell lung cancer (NSCLC).

Among the challenges are a lack of reliable biomarkers and resistance in some patients who have squamous cell carcinoma (SCC).

Molecular differences may help explain geographic gaps in outcomes.

A new report finds despite reforms to the country’s health care system, many patients in China with lung cancer experience stress, and sometimes health consequences, on account of the disease’s financial burden.

In the absence of a head-to-head trial, the researchers compiled data from randomized controlled trials of the 2 PD-1/PD-L1 inhibitors in patients with advanced disease and PD-L1 ≥ 50%.

Targeted therapies have improved outcomes for patients with lung cancer, but the goal needs to be tailoring the right therapy to the right patient, said Ticiana Leal, MD, associate professor, director of the Thoracic Medical Oncology Program, Department of Hematology and Medical Oncology, Emory University School of Medicine.

During the Quality Cancer Care Alliance Summer 2022 National Leadership Summit, Hatim Husain, MD, discusses how HER2 exploration in lung cancer differs from that in breast cancer, as well as novel therapies being explored for HER2 and other disease targets.

IMpower010 trial data may influence a significant evolution in treatment of non–small cell lung cancer.

With these new findings coming from the EMPOWER-Lung 3 trial, the anti-programmed cell death-1 inhibitor cemiplimab is now just the second of its kind to show efficacy in these patients as both monotherapy and as a combination regimen, regardless of histology.

Biomarker testing should be done on all patients with an initial diagnosis of advanced nonsquamous non–small cell lung cancer, but the testing rates in the real world are lower than they should be, particularly for underserved or minority populations, said Ticiana Leal, MD, associate professor, director of the Thoracic Medical Oncology Program, Department of Hematology and Medical Oncology, Emory University School of Medicine.

A study carried out at 4 health care systems found rates of stage I lung cancer increased, and rates of stage IV cancer decreased, once screening was initiated.

Hatim Husain, MD, discusses how National Comprehensive Cancer Network (NCCN) treatment guidelines adjust to meet the treatment needs of patients with lung cancer.

An updated national coverage determination from CMS about lung cancer screening has some stakeholders concerned that the quality of decision-making tools used by providers and patients may weaken.

Hatim Husain, MD, associate professor in the Department of Medicine at UC San Diego, discuses must-haves for successful biomarker testing in lung cancer—in particular, non–small cell lung cancer (NSCLC)—and how the field is adapting to the targeted treatment needs of its patients.

A significant subset of patients continues to receive chemotherapy monotherapy despite the availability of newer approaches, including programmed cell death protein-1 (PD-1) and programmed death ligand-1 (PD-L1) inhibitors.

Edward Arrowsmith, MD, concludes with his thoughts on developing therapies and how they are implemented into clinical pathways for NSCLC treatment.

Dr Arrowsmith discusses the role immune checkpoint inhibitors play in NSCLC therapy, both as monotherapy and in combination therapy.

Results from DESTINY-Lung01 have shown promising progression-free survival and overall survival with ongoing research that may lead to a future FDA approval in non–small cell lung cancer (NSCLC), said Ticiana Leal, MD, associate professor, director of the Thoracic Medical Oncology Program, Department of Hematology and Medical Oncology, Emory University School of Medicine.